ImmuCell Corporation (ICCC) - Q3 2025 10-Q Summary
Business Context and Reporting Period
ImmuCell Corporation is an animal health company focused on dairy and beef cattle, specifically targeting the first 30 days of life (scours prevention via the First Defense product line) and the first 30 days of lactation (mastitis treatment via the Re-Tain product line). This report covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Product Sales | $5.51 million | $6.01 million | $20.02 million | $18.74 million |
| Gross Margin | $2.36 million (43%) | $1.58 million (26%) | $8.53 million (43%) | $5.11 million (27%) |
| Net Operating Income (Loss) | $20,075 | ($574,894) | $1.71 million | ($2.26 million) |
| Net Income (Loss) | ($139,748) | ($701,690) | $1.81 million | ($2.67 million) |
| Cash and Equivalents | $3.89 million (as of Sept 30, 2025) | |||
| Total Debt | $9.49 million (as of Sept 30, 2025) | |||
| Operating Cash Flow (YTD) | $1.99 million | $0.36 million |
Material Changes vs. Prior Period
- Profitability Turnaround: The company swung from a net operating loss of $575k in Q3 2024 to a net operating income of $20k in Q3 2025. Year-to-date, the company reported a net income of $1.81 million compared to a net loss of $2.67 million in the prior year.
- Gross Margin Expansion: Gross margin percentage improved significantly to 43% in Q3 2025 (up from 26% in Q3 2024) due to restored production capacity and reduced scrap costs following contamination events in 2023-2024.
- Revenue Trends: Q3 2025 sales decreased 8% year-over-year ($5.51M vs $6.01M) as the company cleared a significant backlog of orders accumulated during prior supply shortages. However, YTD sales increased 7%.
- Debt Refinancing: In Q3 2025, the company refinanced approximately $2.3 million of existing debt (Loans #6 and #7) into a new loan (Loan #8) at a reduced fixed interest rate of 6.5%, removing balloon payments due in 2026.
- Inventory Build: Inventory increased to $9.8 million (from $7.1 million at year-end 2024) as the company rebuilt buffer stocks after resolving production backlogs.
Guidance, Outlook, and Risks
- Re-Tain Development: The company is awaiting FDA approval for Re-Tain, a novel mastitis treatment. The critical path constraint is currently the resolution of inspectional observations at the contract manufacturer's facility. The company has placed Re-Tain development in an "aggressive idle" status to conserve cash while maintaining regulatory pursuit.
- Production Capacity: First Defense production capacity has been restored to approximately $30 million annually. The company is evaluating a $3 million investment to expand capacity to $40 million but has deferred the full investment pending cash availability.
- Liquidity: Management projects that existing cash ($3.89M) and anticipated gross margins are sufficient to fund operations for at least the next 12 months.
- Key Risks:
- Debt Covenants: The company must meet a minimum Debt Service Coverage (DSC) ratio of 1.35 for the year ending December 31, 2025. The trailing twelve-month DSC ratio as of September 30, 2025, was 2.96.
- Contamination: Recurring production contamination events remain a risk, though recent remediation steps have improved yields. Scrap costs of approximately $410k impacted YTD 2025 margins.
- Customer Concentration: Two distributors accounted for 73% of sales and 68% of accounts receivable in the YTD period.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the company's ability to maintain the 1.35 DSC ratio for the full year 2025, given the seasonal nature of sales.
- Re-Tain FDA Status: Monitor updates on the contract manufacturer's facility inspection and the timeline for the final Chemistry, Manufacturing, and Controls (CMC) approval.
- Scrap and Yield Rates: Track future quarters for recurrence of production contamination and its impact on the 43% gross margin target.
- Backlog Normalization: Assess whether Q3 2025 sales decline represents a permanent softening or a temporary normalization after clearing the backlog.
- Capital Expenditure Plans: Confirm the timeline and funding source for the proposed $3 million expansion of First Defense production capacity.